卡格列净和二甲双胍在2型糖尿病合并轻度阻塞性睡眠呼吸暂停综合征中的应用效果

doi:10.20047/j.issn1673-7210.2023.14.25

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (634 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the effects of Canagliflozin and Metformin in type 2 diabetes mellitus (T2DM) combined with mild obstructive sleep apnea hypopnea syndrome (OSAHS). Methods Sixty patients with T2DM complicated with mild OSAHS admitted to Baise People’s Hospital of Guangxi Zhuang Autonomous Region from June 2020 to June 2021, according to random number table method, they were divided into Canagliflozin group and Metformin group, with 30 cases in each group. Canagliflozin group received Canagliflozin orally and Metformin group received Metformin orally, all were treated for 12 weeks. Blood glucose index, blood lipid index, body mass index (BMI), blood pressure, ventilation function, and the occurrence of adverse reactions were compared between the two groups before and after treatment. Results After treatment, fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, and insulin resistance index of the two groups were lower than before treatment, the differences were statistically significant (P＜0.05), but there was no statistical significance between the two groups (P＞0.05). After treatment, total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in both groups were lower than before treatment, while high density lipoprotein cholesterol (HDL-C) was higher than before treatment, and TC, TG, and LDL-C in Canagliflozin group were lower than those in Metformin group, while HDL-C was higher than those in Metformin group. After treatment, BMI, systolic blood pressure, diastolic blood pressure, and apnea hypopnea index (AHI) in Canagliflozin group were lower than before treatment, and lowest percutaneous arterial oxygen saturation (LSpO2) was higher than before treatment, and BMI, systolic blood pressure, diastolic blood pressure, and AHI in Canagliflozin group were lower than those in Metformin group, while LSpO2 was higher than those in Metformin group, the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion Compared with Metformin, Canagliflozin can not only effectively improve blood glucose and lipid levels in T2DM patients with mild OSAHS, but also effectively improve blood pressure, ventilation function and weight loss.

Key words： Type 2 diabetes mellitus Obstructive sleep apnea hypopnea syndrome Canagliflozin Metformin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Bin1　YU Fei2▲　WANG Yong1　PAN Meishi1　LIN Zhiyuan1

Cite this article:

YANG Bin1　YU Fei2▲　WANG Yong1　PAN Meishi1　LIN Zhiyuan1. Efficacy of Canagliflozin and Metformin in type 2 diabetes mellitus combined with mild obstructive sleep apnea syndrome[J]. 中国医药导报, 2023, 20(14): 118-122.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.14.25 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I14/118

[1] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志，2021，13（4）：315-409.
[2] 中华医学会呼吸病学分会睡眠呼吸学组，中华医学会糖尿病学分会.阻塞性睡眠呼吸暂停与糖尿病专家共识[J].中华糖尿病杂志，2010，2（2）：91-96.
[3] Umoh VA，Akpan EE，Ekrikpo UE，et al. The Risk of Obstructive Sleep Apnea among Patients with Type 2 Diabetes Mellitus [J]. Niger Med J，2020，61（1）：32-36.
[4] Foster GD，Sanders MH，Millman R，et al. Obstructive sleep apnea among obese patients with type 2 diabetes[J]. Diabetes Care，2009，32（6）：1017-1019.
[5] 中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.成人阻塞性睡眠呼吸暂停基层诊疗指南（实践版·2018）[J].中华全科医师杂志，2019，18（1）：30-35.
[6] Asad K，Fariha S，Aaron B，et al. Effect of Metformin on the Severity of Obstructive Sleep Apnea in Patients With Diabetes Mellitus （Type 2） [J]. Meeting Abstracts，2011，140（4）： 821A.
[7] 《改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议》工作组.改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议[J].中国循环杂志，2020，35（3）：231-238.
[8] 中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.2型糖尿病基层诊疗指南（实践版·2019）[J].中华全科医师杂志，2019，18（9）：810-818.
[9] 中华医学会糖尿病学分会，中华医学会内分泌学分会.中国成人2型糖尿病患者糖化血红蛋白控制目标及达标策略专家共识[J].中华内分泌代谢杂志，2020，36（1）：14-24.
[10] 姜菲，刘岩，任丽珏，等.阻塞性睡眠呼吸暂停综合征与2型糖尿病慢性并发症的相关性研究[J].中国实用内科杂志，2019，39（11）：977-980.
[11] 母义明，纪立农，宁光，等.二甲双胍临床应用专家共识（2018年版）[J].中国糖尿病杂志，2019，27（3）：161-173.
[12] 纪立农，郭立新，郭晓蕙，等.钠-葡萄糖共转运蛋白2（SGLT2）抑制剂临床合理应用中国专家建议[J].中国糖尿病杂志，2016，24（10）：865-870.
[13] 中国研究型医院学会糖尿病学专业委员会.成人2型糖尿病患者口服降糖药物三联优化方案（二甲双胍+二肽基肽酶4抑制剂+钠-葡萄糖共转运蛋白2抑制剂）中国专家共识[J].中国糖尿病杂志，2021，29（8）：561-570.
[14] Tsapas A，Avgerinos I，Karagiannis T，et al. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes：A Systematic Review and Network Meta-analysis [J]. Ann Intern Med，2020，173（4）：278-286.
[15] 中华医学会内分泌学分会脂代谢学组.中国2型糖尿病合并血脂异常防治专家共识（2017年修订版）[J].中华内分泌代谢杂志，2017，33（11）：925-936.
[16] 姬秋和，陈莉明，郗光霞，等.2型糖尿病患者体重管理专家共识[J].国际内分泌代谢杂志，2022，42（1）：78-86.
[17] Humer E，Pieh C，Brandmayr G. Metabolomics in Sleep，Insomnia and Sleep Apnea [J]. Int J Mol Sci，2020，21（19）：7244.
[18] 唐珊珊，彭永德.钠-葡萄糖共转运蛋白2抑制剂调控代谢及心肾获益机制的研究进展[J].中华糖尿病杂志，2020，12（8）：661-664.
[19] Tuttle KR，Brosius FC 3rd，Cavender MA，et al. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes：Report of a Scientific Workshop Sponsored by the National Kidney Foundation[J]. Am J Kidney Dis，2021，77（1）：94-109.
[20] Cai X，Ji L，Chen Y，et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients：A meta-analysis [J]. J Diabetes Investig，2017，8（4）：510-517.
[21] Schork A，Saynisch J，Vosseler A，et al. Effect of SGLT2 inhibitors on body composition，fluid status and renin-angiotensin-aldosterone system in type 2 diabetes：a prospective study using bioimpedance spectroscopy [J]. Cardiovasc Diabetol，2019，18（1）：46.
[22] Salman LA，Shulman R，Cohen JB. Obstructive Sleep Apnea，Hypertension，and Cardiovascular Risk：Epidemiology，Pathophysiology，and Management [J]. Curr Cardiol Rep，2020，22（2）：6.
[23] 中国医师协会呼吸医师分会睡眠呼吸障碍工作委员会，“华佗工程”睡眠健康项目专家委员会.成人阻塞性睡眠呼吸暂停低通气综合征远程医疗临床实践专家共识[J].中华医学杂志，2021，101（22）：1657-1664.
[24] Yamagishi S，Matsui T. Protective Role of Sodium-Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes [J]. Rejuvenation Res，2016，19（2）：107- 114.
[25] Woods TC，Satou R，Miyata K，et al. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus [J]. Am J Nephrol，2019，49（4）：331-342.
[26] 战涛，高士更，刘平国.男性重度阻塞性睡眠呼吸暂停低通气综合征患者焦虑抑郁症状研究[J].当代医学，2021，27（6）：158-160.
[27] 王海月，燕存子，戴月梅，等.阻塞性睡眠呼吸暂停低通气综合征患者Epworth嗜睡评分与甲状腺激素的相关性[J].疑难病杂志，2021，20（3）：232-236.